ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Uric Acid, Urate"

  • Abstract Number: L05 • ACR Convergence 2024

    Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels

    Christian Schwabe1, Orit Cohen Barak2, Alexandra Cole3, Hadar Reuveni2, Liron Shelev2, Liora Blinder-Haddad2 and Nicola Dalbeth4, 1NZCR, Auckland, New Zealand, 2Protalix Ltd, Karmiel, Israel, 3NZCR, Christchurch, New Zealand, 4University of Auckland, Auckland, New Zealand

    Background/Purpose: PEGylated uricases have already demonstrated therapeutic modality in the treatment of refractory gout patients. PRX-115 is a recombinant homotetrameric uricase enzyme, produced from Candida…
  • Abstract Number: 2008 • ACR Convergence 2024

    A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Dose of ABP-671 in Participants with Chronic Kidney Disease (CKD)

    ullrich schwertschlag1, william dongfang Shi2, rOBERT PERRY3, Kwabena Ayesu4, rOY WU5, jerry liu6, JinSying Lin7 and Adam Jin8, 1Atombio Science, PALO ALTO, CA, 2Jiangsu Atom Bioscience,, Suzhou, Jiangsu, China (People's Republic), 3Panax Clin Res, Miami Lakes, FL, 4OMEGARLLC, ORLANDO, FL, 5Atom Bioscience, SAN FRANCISCO, CA, 6atombio, San Diego, CA, 7Biostatconsulting, Wuzhong, Suzhou, Jiangsu, China (People's Republic), 8atom biosciences, Wuzhong, Suzhou, Jiangsu, China (People's Republic)

    Background/Purpose: In this open-label Phase 1 study, 22 participants were enrolled in 3 cohorts, 10 participants with normal kidney function (eGFR ≥90 ml/min/1.73m2 and no…
  • Abstract Number: 2012 • ACR Convergence 2024

    Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial

    Orrin Troum1, John Botson2, Fang Fang3, Katie Obermeyer3, Supra Verma3 and Brian LaMoreaux4, 1Providence Health Care/Doctor's of St John's (MDSJ) Santa Monica, CA, Santa Monica, CA, 2Orthopedic Physicians Alaska, Anchorage, AK, 3Amgen, Inc., Thousand Oaks, CA, 4Amgen, Inc., Deerfield, IL

    Background/Purpose: Pegloticase, infused every 2 weeks over ≥2 hrs, lowers serum urate (SU) in patients with refractory gout. Decreasing infusion time is expected to improve…
  • Abstract Number: 2013 • ACR Convergence 2024

    Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities

    Lenka Hasikova1, Petr Kozlik2, Kveta Kalikova3, Petr Dusek4, Marketa Pavlikova1, Blanka Stiburkova5 and Jakub Závada6, 1Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, 3Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, 4Department of Neurology and Centre of Clinical Neuroscience and Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic, Prague, Czech Republic, 5Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, 6Institute of Rheumatology and Charles University, Praha, Czech Republic

    Background/Purpose: Uric acid (UA) can be non-enzymatically oxidized into allantoin and other products by reactive oxygen species under conditions of increased oxidative stress. Consequently, allantoin…
  • Abstract Number: 0265 • ACR Convergence 2024

    Performance of Two Gout Remission Definitions in a Two-Year Randomized Controlled Trial of Nurse-led Care

    Dansoa Tabi-Amponsah1, Michael Doherty2, Aliya Sarmanova3, Weiya Zhang2, Sarah Stewart4, William Taylor5, Lisa Stamp6 and Nicola Dalbeth7, 1The University of Auckland, Auckland, New Zealand, 2Academic Rheumatology, School of Medicine, University of Nottingham; Pain Centre Versus Arthritis, University of Nottingham, Nottingham, United Kingdom, 3Roche Diagnostics International, Clinical Development and Medical Affairs, Nottingham, England, United Kingdom, 4Auckland University of Technology, Auckland, New Zealand, 5The University of Otago, Wellington, Wellington, New Zealand, 6University of Otago, Christchurch, Christchurch, New Zealand, 7University of Auckland, Auckland, New Zealand

    Background/Purpose: To compare the performance of the 2016 preliminary gout remission definition and a simplified gout remission definition in a clinical trial of nurse-led gout…
  • Abstract Number: 2014 • ACR Convergence 2024

    Effect of a Whole Food Plant-Based Diet in Patients with Gout: A Pilot Randomized Controlled Trial

    Anna Kretova1, Carlijn Wagenaar1, Wendy Walrabenstein2, Daisy Vedder2, Dirkjan van Schaardenburg2 and Martijn Gerritsen1, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Amsterdam UMC, Amsterdam, Netherlands

    Background/Purpose: An unhealthy diet is an important modifiable risk factor for hyperuricemia and gout and is also associated with obesity and metabolic syndrome (MetS), known…
  • Abstract Number: 0266 • ACR Convergence 2024

    Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol

    Dansoa Tabi-Amponsah1, Lisa Stamp2, Anne Horne3, Jill Drake4, Sarah Stewart5, Gregory Gamble3, Keith Petrie1 and Nicola Dalbeth3, 1The University of Auckland, Auckland, New Zealand, 2University of Otago, Christchurch, Christchurch, New Zealand, 3University of Auckland, Auckland, New Zealand, 4University of Otago, Christchurch, New Zealand, 5Auckland University of Technology, Auckland, New Zealand

    Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…
  • Abstract Number: 2018 • ACR Convergence 2024

    Non-adherence to Urate Lowering Therapy in Gout After 5 Years Is Related to Poor Outcomes – Results from the NOR-Gout Study

    Tillmann Uhlig1, Lars F Karoliussen1, Joseph Sexton2, Sella A. Provan2, Espen A. Haavardsholm3, Nicola Dalbeth4 and Hilde B Hammer1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 3Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 4University of Auckland, Auckland, New Zealand

    Background/Purpose: People with gout need to adhere to medication over time to achieve good outcomes. We assessed self-reported adherence to medication with urate lowering therapy…
  • Abstract Number: 0275 • ACR Convergence 2024

    Targeting IRAK4 in Monosodium Urate Crystals Induced Inflammation

    Sadiq Umar1 and Sriram Ravindran2, 1University of Illinois at Chicago, Chicago, IL, 2University of Illinois, Chicago

    Background/Purpose: Gout, the leading cause of inflammatory arthritis, is becoming increasingly prevalent worldwide, affecting both developed and developing countries. This condition results from the deposition…
  • Abstract Number: 2019 • ACR Convergence 2024

    Safety and Efficacy of SEL-212 in the US and ex-US Subgroups: Results from the Phase 3 DISSOLVE Studies

    Michael Pillinger1, Alan Kivitz2, Atul Singhal3, Anand Patel4, Rehan Azeem5, Aletta Falk6, Bhavisha Desai7, Hugues Santin-Janin8 and Herbert Baraf9, 1New York University Grossman School of Medicine, New York,, NY, 2Altoona Center for Clinical Research, Duncansville, PA, 3Southwest Arthritis Research Group, Mesquite, TX, 4Conquest Research, Winter Park, FL, 5Sobi Inc., Waltham, MA, 6Sobi, Stockholm, Sweden, 7Sobi, Glastonbury, CT, 8Sobi, BETTENDORF (68560), France, 9Center for Rheumatology and Bone Research, Wheaton, MD

    Background/Purpose: The DISSOLVE Phase 3 study program investigated the efficacy and safety of SEL-212, a novel, once-monthly, two-component infusion therapy consisting of pegadricase (SEL-037, a…
  • Abstract Number: 0279 • ACR Convergence 2024

    Macrophage Intracellular Fates of Monosodium Urate and Calcium Pyrophosphate Crystals: Phagocytosis, Exchanged/expulsion and Dissolution of Crystals

    Charles Leroy1, Nghia Pham2, François Brial3, Brenda Kischkel4, gwénaêlle Jayat5, Elena Ishow6, Christèle Combes7, Leo Joosten4, Augustin Latourte8, Pascal Richette9 and Hang-Korng Ea10, 1Inserm 1132 / Université Paris Cité, levallois-perret, France, 2INSERM 1132, BIOSCAR, Lariboisière hospital, Paris, France, 3Inserm 1132/ Université Paris Cité, Paris, France, 4Radboudumc, Nijmegen, Netherlands, 5Université Paris cité / Inserm 1132, paris, France, 6Université de Nantes / Ceisam, Nantes, France, 7INP-ENSIACET, Toulouse, France, 8AP-HP, Paris, France, 9Lariboisière Hospital, Paris, France, 10Université Paris Cité, INSERM UMR 1132 BIOSCAR, Paris, France

    Background/Purpose: Gout, due to the presence of monosodium urate crystals (MSU) and calcium pyrophosphate (CPP) crystal deposition disease are both responsible for recurrent inflammation flares.…
  • Abstract Number: 2023 • ACR Convergence 2024

    A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout

    Frank Fan1, Riyong Liu1 and Yu Wang2, 1Chongqing PegBio Biopharm Co.,Ltd., Chongqing, China (People's Republic), 2Hangzhou Grand Biologic Pharmaceutical, Inc., Hangzhou, China (People's Republic)

    Background/Purpose: For patients with refractory chronic gout, i.e., those who have frequent gout flares and/or persistent tophi despite treatment with the highest tolerable doses of…
  • Abstract Number: 0280 • ACR Convergence 2024

    Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform

    Mark Russell1, Jon Massey2, Edward Roddy3, Brian MacKenna4, Seb Bacon4, Ben Goldacre4, Colm Andrews4, George Hickman4, Amir Mehrkar2, Arti Mahto5, Andrew Rutherford6, Samir Patel1, Maryam Adas7, Edward Alveyn7, deepak Nagra1, Katie Bechman7, Joanna Ledingham8, Joanna Hudson9, Sam Norton1, Andrew Cope7 and James Galloway10, 1King's College London, London, England, United Kingdom, 2University of Oxford, Oxford, England, United Kingdom, 3Keele University, Keele, England, United Kingdom, 4University of Oxford, Oxford, United Kingdom, 5King's College Hospital NHS Foundation Trust, London, United Kingdom, 6King's College Hospital NHS Foundation Trust, London, England, United Kingdom, 7King's College London, London, United Kingdom, 8Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, 9King's College London, King's College London, United Kingdom, 10Centre for Rheumatic Diseases, King's College London, London, United Kingdom

    Background/Purpose: Data from before the COVID-19 pandemic had shown persistently poor care for people with gout in many countries worldwide. Whether this was further exacerbated…
  • Abstract Number: 2127 • ACR Convergence 2024

    Relationship Between Serum Uric Acid and Trabecular Bone Score (TBS) in Healthy Population

    Isabella Silvestre Ignarro1, Gabriela Tieme Ochikubo2, Liliam Takayama3, Valeria de falco Caparbo2, Camille Pinto Figueiredo2, Marcos Rafael Nogueira Cavalcanti1, Angelita Gomes De Souza1, Isabela Judith Martins Bensenor1, Ricardo Fuller1 and Diogo Domiciano4, 1Bone Metabolism Laboratory, Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 2Bone Metabolism Laboratory, Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, São Paulo, SP, Brazil, 3Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, São Paulo, SP, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil

    Background/Purpose: Serum uric acid (UA) has been postulated to play a role against bone loss due to antioxidant mechanisms. Some studies have shown association between…
  • Abstract Number: 0907 • ACR Convergence 2024

    Association of Rare and Common Genetic Variants in MOCOS with Inadequate Response to Allopurinol

    Niamh Fanning1, Murray Cadzow2, Ruth Topless3, Chris Frampton4, Nicola Dalbeth5, Tony Merriman6 and Lisa Stamp4, 1University of Otago, Christchurch, New Zealand, 2University of Otago, Dunedin 9054, New Zealand, 3University of Otago, Dunedin, New Zealand, 4University of Otago, Christchurch, Christchurch, New Zealand, 5University of Auckland, Auckland, New Zealand, 6University of Alabama at Birmingham, Homewood, AL

    Background/Purpose: The minor allele of the common rs2231142 (Q141K) ABCG2 variant predicts inadequate response to allopurinol urate lowering therapy (ULT). We hypothesize that additional variants in genes…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology